Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · IEX Real-Time Price · USD
19.31
+0.11 (0.57%)
Apr 19, 2024, 4:00 PM EDT - Market closed
Castle Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 32.11, with a low estimate of 25 and a high estimate of 40. The average target predicts an increase of 66.29% from the current stock price of 19.31.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 1, 2024.
Analyst Ratings
The average analyst rating for CSTL stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +45.00% | Mar 1, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $33 → $37 | Buy | Maintains | $33 → $37 | +91.61% | Mar 1, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +29.47% | Dec 14, 2023 |
| Keybanc | Keybanc | Buy Maintains $37 → $25 | Buy | Maintains | $37 → $25 | +29.47% | Aug 4, 2023 |
| Lake Street | Lake Street | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +65.72% | Jul 7, 2023 |
Financial Forecast
Revenue This Year
241.98M
from 219.79M
Increased by 10.10%
Revenue Next Year
262.46M
from 241.98M
Increased by 8.46%
EPS This Year
-2.18
from -2.14
EPS Next Year
-1.93
from -2.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 251.0M | 278.3M | 316.1M | 412.9M | 462.6M |
| Avg | 242.0M | 262.5M | 295.8M | 401.1M | 449.4M |
| Low | 230.7M | 242.1M | 274.5M | 385.3M | 431.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.2% | 15.0% | 20.4% | 39.6% | 15.4% |
| Avg | 10.1% | 8.5% | 12.7% | 35.6% | 12.1% |
| Low | 5.0% | 0.0% | 4.6% | 30.3% | 7.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.25 | -0.57 | -0.09 | 1.43 | 2.31 |
| Avg | -2.18 | -1.93 | -0.71 | 1.39 | 2.24 |
| Low | -2.73 | -2.72 | -1.00 | 1.33 | 2.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 66.5% |
| Avg | - | - | - | - | 61.8% |
| Low | - | - | - | - | 55.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.